Condition
ctDNA Monitoring
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Not Yet Recruiting2
Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07366112Phase 2Not Yet Recruiting
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
NCT06970912Phase 2Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
NCT07292207Phase 2Not Yet RecruitingPrimary
Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer
NCT05635630Not ApplicableUnknown
Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention
Showing all 4 trials